Ertumaxomab


Ertumaxomab is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.
It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.
Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.